Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: J Rheumatol. 2013 Feb 15;40(5):605–610. doi: 10.3899/jrheum.120941

Table 2.

Treatment of myocardial infarction (MI) patients with and without rheumatoid arthritis (RA)

Treatment MI
patients
with RA
(N = 77)		 MI patients
without RA
(N = 154)		 Odds ratio
(95% CI)
Reperfusion therapy, n (%) 39 (50%) 73 (47%) 1.19 (0.63, 2.23)
Medications during hospitalization, n (%)
Aspirin 56 (72%) 127 (81%) 0.44 (0.18, 1.09)
ACE Inhibitor 25 (32%) 58 (37%) 0.78 (0.41, 1.48)
Beta Blocker 54 (69%) 115 (74%) 0.83 (0.40, 1.71)
Statin 24 (31%) 61 (39%) 0.58 (0.25, 1.30)
Other lipid-lowering agents 0 (0%) 5 (3%) 0.99
Other anti-platelet agents 31 (40%) 71 (46%) 0.31
Medications at discharge, n (%)
Aspirin 49 (63%) 99 (63%) 0.93 (0.45, 1.95)
ACE Inhibitor 23 (29%) 51 (33%) 0.91 (0.46, 1.78)
Beta Blocker 48 (62%) 92 (59%) 1.45 (0.67, 3.13)
Statin 29 (37%) 58 (37%) 1.12 (0.50, 2.48)
Other lipid-lowering agents 0 (0%) 3 (2%) 0.99
Other anti-platelet agents 29 (40%) 55 (39%) 0.82